Диссертация (1146667), страница 18
Текст из файла (страница 18)
— 2016. —Vol. 11№ 2. Режим доступаwww.plosone.org9826. Arboleya S. Establishment and development of intestinal microbiota inpreterm neonates / Arboleya S., Binetti A., Salazar N. [et al.] // FEMS MicrobiolEcol. — 2012. — Vol. 79. —P. 763–772.27. Archbald-Pannone L. Diarrhea, Clostridium difficile, and intestinalinflammation in residents of a long-term care facility/ Archbald-Pannone L.,Sevilleja J.E., Guerrant R. // J.Am.Med.Dir.Assoc. —2010. — Vol.
11. —P. 263–267.28. Bartlett J.G. Clindamycin- associated colitis due to a toxin-producingspecies of Clostridium in hamsters / Bartlett J.G, Onderdonk A.B. [et al.] // J InfectDis. — 1977. — Vol. 136. — P. 701–705.29. Bauer M. European Society of Clinical Microbiology and InfectiousDiseases (ESCMID): treatment guidance document for Clostridium difficileinfection (CDI) / Bauer M., Kuijper E., van Dissel J. // Clin. Microbiol. Infect.
–2009. — Vol. 15. —P. 1067–1079.30. Bauer M.P. ECDIS Study Group. Clostridium difficile infection inEurope: a hospital-based survey/ Bauer M.P, Notermans D.W, van Benthem B.H. [etal.]// Lancet. — 2011. — Vol. 377, №63. —P.73.31. Bloomfield M.G. Risk factors for mortality in Clostridium difficileinfection in the general hospital population: a systematic review / Bloomfield M.G.,Sherwin J.C. [et al.] //Journal of Hospital Infection. —2012. — Vol.
82. —P. 1-12.32. Borody T.J. Fecal microbiota transplantation and emerging applications /Borody T.J, Khoruts A. // Nat Rev Gastroenterol Hepatol. — 2012. — Vol. 9. —P.88-96.33. Brouwer M. S. Horizontal gene transfer converts non-toxigenicClostridium difficile strains into toxin producers/ Brouwer M. S., Roberts A.P. [etal.] // Nature.
—2013. —4: e3601.9934. Büchler A.C., Rampini S. K., Stelling S., et al. Antibiotic susceptibility ofClostridium difficile is similar worldwide over two decades despite widespread useof broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich.[Электронный доступ] // BMC Infectious Diseases. —2014. —Vol.
14. Режимдоступа www. bmcinfectdis.biomedcentral.com35. Burke K. E. Clostridium difficile Infection: A Worldwide Disease/ BurkeE. and Lamont J. // Gut and Liver. — 2014. — Vol. 8, №1. — P.1—636. Carter G. The anti-sigma factor TcdC modulates hypervirulence in anepidemic BI/NAP1/027 clinical isolate of Clostridium difficile [Электронныйдоступ] / Carter G, Douce G. [et al.] // PLoS Pathog. — 2011. — Vol. 7, №10.Режим доступа www.plosone.org37. Chambers C. J.
Structure and function of a Clostridium difficile sortaseenzyme [Электронный доступ] / Chambers C. J., Roberts A. K. [et al.] // Scientificreports. —2015. —Vol. 5. Режим доступа www. bmcinfectdis.biomedcentral.com38. Chandrabali Gh. Clostridium difficile infection in the twenty-firstcentury// Emerging Microbes and Infections. — 2013. — Vol. 2. Режим доступаhttp://www.nature.com/emi/journal/39. Claesson M.J. Composition, variability, and temporal stability of theintestinal microbiota of the elderly/ Claesson M.J., Cusack S., O’Sullivan O.
[et al.]// Proc Natl Acad Sci . — 2011. — Vol. 108. — P. 4586–4591.40. Cobo E.R. Colonic MUC2mucin regulates the expression andantimicrobial activity of b-defensin 2 / Cobo E.R, Kissoon-Singh V. [et al.] //Mucosal Immunology. — 2015. — Vol. 8,№ 6. — P. 1360-1372.41. Cohen O. R. Systemically Administered IgG Anti-Toxin AntibodiesProtect the Colonic Mucosa during Infection with Clostridium difficile in the PigletModel/ Cohen O. R., Steele J. A. // Plos One.
— 2014. —Vol. 9. Режим доступаwww.plosone.org10042. Collins D.A. Epidemiology of Clostridium difficile infection in Asia/Collins D.A., Hawkey P.M. [et al.] // Antimicrob. Resist. Infect. Control. —2013.— Vol. 2 №1. Режим доступа https://www.ncbi.nlm.nih.gov/pubmed/43. Committee On Infectious Diseases. Clostridium difficile Infection inInfants and Children. // Pediatrics. —2013.
— Vol. 131. — P. 196–200.44. Compare D. The role of gut microbiota in the pathogenesis andmanagement of allergic diseases/ Compare D., Nardone G. // European Review forMedical and Pharmacological Sciences. — 2013. — Vol. 17, №2. — P. 11—1745.
Czepiel J. The role of local and systemic cytokines in patients infectedwith Clostridium difficile / Czepiel J., Biesiada G. [et al.] //Journal of physiologyand pharmacology. — 2014. — Vol. 65,№ 5. —P. 695-703.46. Debast S. B. European Society of Clinical Microbiology and InfectiousDiseases: update of the treatment guidance document for Clostridium difficileinfection (CDI) / Debast S. B., Bauer M. P. // Clinical Microbiology and Infection.— 2014. —Vol.
20, № 2. — P. 1—26.47. Dingle K.E, et al. Clinical Clostridium difficile: clonality andpathogenicity locus diversity.// PLoS One. — 2011. — Vol. 6. Режим доступаwww.plosone.org48. Dobreva E.G. Advances in molecular surveillance of Clostridium difficilein Bulgaria/ Dobreva E.G., Ivanov I.N. [et al.] // J. Med. Microbiol. —2013.
— Vol.62, № 9. —P. 1428–1434.49. Dodek P.M. Length of stay and mortality due to Clostridium difficileinfection acquired in the intensive careunit / Dodek P.M., Norena M., Ayas N.T. [etal.] // J Crit Care. — 2013. — Vol. 28. —P. 335–340.50. Donald R.G. A novel approach to generate a recombinant toxoid vaccineagainst C.
difficile/ Donald R.G, Flint M. [et al.] // Microbiology. —2013. — Vol.159. — P. 1254–1266.10151. Donelli G. Biofilm-growing intestinal anaerobic bacteria /Donelli G.,Vuotto C., Cardines R., Mastrantonio P. // FEMS Immunol Med Microbiol. —2012.— Vol. 65. —P. 318–325.52. Du P. Sequence variation in tcdA and tcdB of Clostridium difficile: ST37with truncated tcdA is a potential epidemic strain in China / Du P., Cao B., Wang J.[et al.] // J. Clin. Microbiol.
—2014. — Vol. 52, №9. — P. 3264–3270.53. Eckert C. Contamination of ready-to-eat raw vegetables with Clostridiumdifficile in France / Eckert C., Burghoffer B., F.Barbut. // Journal of MedicalMicrobiology. —2013. — Vol. 62. —P. 1435–1438.54. Elliott B. Evolutionary History of the Clostridium difficile PathogenicityLocus / Elliott B., Dingle K. E. [et al.] // Genome Biol. E—2014. — Vol. 6,№ 1. —P. 36–52.55. Elliott B. The Complexity and Diversity of the Pathogenicity Locus inClostridium difficile Clade 5/ Elliott B., Dingle K.
E.[et al.] // Genome Biol. Evol.—2014. — Vol. 6 ,№ 12. —P. 3159–3170.56. Ethapa T. Multiple factors modulate biofilm formationn by the anaerobicpathogen Clostridium difficile / Ethapa T., Leuzzi R., Ng Y.K. [et al.] // J Bacteriol.—2013.
— Vol. 195. —P. 545–555.57. Eyre D.W. Diverse sources of Clostridium difficile infection identified onwhole-genome sequencing/ Eyre D.W., Cule M.L. [et al.] // N Engl J Med. — 2013.— Vol. 369 ,№ 13. —P. 1195–1205.58. Fallani M. Determinants of the human infant intestinal microbiota afterthe introduction of first complementary foods in infant samples from five Europeancentres / Fallani M., Amarri S., Uusijarvi A. [et al.] // Microbiology. — 2011. —Vol. 157.
—P. 1385–1392.10259. Feghaly R.E. Markers of intestinal inflammation, not bacterial burden,correlate with clinical outcomes in Clostridium difficile infection / Feghaly R.E,Stauber J.L. [et al.] // Clin Infect Dis. —2013. — Vol. 56. — P.1713-1721.60. Flint H.J. The role of the gut microbiota in nutrition and health/ Flint H.J.,Scott K.P., Louis P. [et al.] // Nat Rev Gastroenterol Hepatol. —2012. — Vol. 9. —P. 577–589.61.
Foglia G. Clostridium difficile: development of a novel candidate vaccine/Foglia G., Shah S., Luxemburger C. [et al.] // Vaccine. —2012. — Vol. 30. —P.4307–4309.62. Forster A.J. The effect of hospital-acquired infection with Clostridiumdifficile on length of stay in hospital/ Forster A.J., Taljaard M., Oake N. [et al.] //CMAJ. — 2012.
— Vol. 184. — P. 37–42.63. Foster L.M. A comprehensive post-market review of studies on aprobiotic product containing Lactobacillus helveticus R0052 and Lactobacillusrhamnosus R0011/ Foster L.M., Tompkins T.A., Dahl W.J.// Beneficial Microbes.—2011. — Vol. 2, № 4. —P. 319-334.64.Fox M. J., Ahuja K.
D. et al. Can probiotic yogurt prevent diarrhea inchildren on antibiotics?A doubleblind, randomised, placebo-controlled study[Электронный доступ] / Fox M. J., Ahuja K. D. [et al.] // BMJ Open. — 2015. —Vol. 5. Режим доступа https://www.ncbi.nlm.nih.gov/pubmed/65. Frantz A.L. Targeted deletion of MyD88 in intestinal epithelial cellsresults in compromised antibacterial immunity associated with downregulation ofpolymeric immunoglobulin receptor, mucin-2, and antibacterial peptides /FrantzA.L., Rogier E.W., Weber C.R. [et al.] // Mucosal Immunol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
